Efalizumab Lifts Quality of Life in Just Two Weeks

Article

Winston-Salem, N.C. - After subcutaneous treatment with efalizumab(Raptiva), patients who achieved 50 to 75 percent improvement in PsoriasisArea and Severity Index (PASI) score reported improvement in quality oflife.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.